| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/12/2010 | WO2010089522A1 Stable formulation of a therapeutic protein |
| 08/12/2010 | WO2010089443A2 PHARMACEUTICAL COMPOSITIONS COMPRISING TGF- β1 INHIBITOR PEPTIDES |
| 08/12/2010 | WO2010089117A1 Structured polycyclic peptide |
| 08/12/2010 | WO2010089116A1 Structured peptide processing |
| 08/12/2010 | WO2010089115A1 Multispecific peptides |
| 08/12/2010 | WO2010089019A1 Compounds comprising n-formyl-methionine residues and tumor-targeting peptides |
| 08/12/2010 | WO2010088924A1 Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| 08/12/2010 | WO2010068688A3 System and method for the delivery of a sanitizing foam |
| 08/12/2010 | WO2010060529A8 Microparticles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone |
| 08/12/2010 | WO2010050787A3 Encapsulated functional fine particle composition capable of spraying and preparation method thereof |
| 08/12/2010 | WO2010045896A3 Polymeric composition with synergistic effect in treatment of tumour diseases |
| 08/12/2010 | WO2010040312A8 Hollow mesoporous silica sphere coated with gold and preparation method thereof and use in cancer therapy |
| 08/12/2010 | WO2010015400A3 Injectable taxane pharmaceutical composition |
| 08/12/2010 | WO2009143367A3 Egf-a domain-mediated modulation of pcsk9 for treating lipid disorders |
| 08/12/2010 | WO2009143345A3 Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders |
| 08/12/2010 | WO2009117410A8 Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques |
| 08/12/2010 | WO2009012303A3 Therapeutic stable nanoparticles |
| 08/12/2010 | US20100204718 Compositions and methods for joining non-conjoined lumens |
| 08/12/2010 | US20100204469 Conjugated psychotropic drugs and uses thereof |
| 08/12/2010 | US20100204457 Preparation of annexin derivatives |
| 08/12/2010 | US20100204448 Method and carrier complexes for delivering molecules to cells |
| 08/12/2010 | US20100204346 Novel sweetener having sucrose-like taste, method for producing the same, and use of the same |
| 08/12/2010 | US20100204345 Aqueous dispersion of low molecular weight polytetrafluoroethylene, low molecular weight polytetrafluoroethylene powder, and method for producing low molecular weight polytetrafluoroethylene |
| 08/12/2010 | US20100204344 Macrocyclic Lactones as Fragrances |
| 08/12/2010 | US20100204343 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and its use as antioxidant |
| 08/12/2010 | US20100204342 Spherical organic polymer-silicon compound composite particles, hollow particles and their production methods |
| 08/12/2010 | US20100204341 Personal care dissolvable films |
| 08/12/2010 | US20100204325 Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| 08/12/2010 | US20100204261 Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| 08/12/2010 | US20100204179 Resveratrol complex and process for the preperation |
| 08/12/2010 | US20100204147 Methods For Delivering Thymosin Beta 4, Analogues, Isoforms and Other Derivatives |
| 08/12/2010 | US20100204102 Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition comprising the same |
| 08/12/2010 | US20100203171 is generated and delivered simultaneously using a syringe based device; comprises a sclerosant liquid, polidocanol solution, and gas N2, xenon; by inter alia causing a localised inflammatory reaction, favor the elimination of varicose veins; low density; half-life |
| 08/12/2010 | US20100203163 Injectable polymer-lipid blend for localized drug delivery |
| 08/12/2010 | US20100203141 Stimuli-responsive low solubility hydrogel copolymers of n-isopropyl acrylamide and synthesis method |
| 08/12/2010 | US20100203138 Controlled Release Composition Comprising a Recombinant Gelatin |
| 08/12/2010 | US20100203133 High drug load tablet |
| 08/12/2010 | US20100203005 Transdermal compositions |
| 08/12/2010 | CA2751633A1 Transdermal pharmaceutical preparations |
| 08/12/2010 | CA2751505A1 Multispecific peptides |
| 08/12/2010 | CA2751460A1 Compositions and uses to govern cancer cell growth |
| 08/12/2010 | CA2751412A1 Methods of reducing the proliferation and viability of microbial agents |
| 08/12/2010 | CA2751039A1 Pharmaceutical composition for oral administration |
| 08/12/2010 | CA2750969A1 Structured peptide processing |
| 08/12/2010 | CA2750559A1 Pharmaceutical formulations of tgf-.beta.1 inhibitor peptides |
| 08/12/2010 | CA2749809A1 Process for purifying guar |
| 08/12/2010 | CA2748314A1 Extended recombinant polypeptides and compositions comprising same |
| 08/12/2010 | CA2746425A1 Clostridial toxin pharmaceutical compositions |
| 08/12/2010 | CA2741209A1 An improved process for pegylation of proteins |
| 08/12/2010 | CA2741052A1 Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| 08/12/2010 | CA2726232A1 Stable formulation of a therapeutic protein |
| 08/11/2010 | EP2216409A1 Albumin fusion proteins |
| 08/11/2010 | EP2216049A1 Drug conjugates with polyglycerols |
| 08/11/2010 | EP2216048A1 Spherical particle and method for producing the same |
| 08/11/2010 | EP2216026A1 Ophthalmic compositions and uses for treating ophthalmic conditions |
| 08/11/2010 | EP2215915A1 Citrulline-containing drink |
| 08/11/2010 | EP2215914A1 Method of improving sweetness qualities of stevia extract |
| 08/11/2010 | EP2215122A1 Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| 08/11/2010 | EP2215107A1 Peptide ligand directed drug delivery |
| 08/11/2010 | EP2214716A2 Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom |
| 08/11/2010 | EP2214715A1 Method of delivering an anti-cancer agent to a cell |
| 08/11/2010 | EP2214714A1 A new class of therapeutics that enhance small molecule diffusion |
| 08/11/2010 | EP2214700A1 Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| 08/11/2010 | EP2214653A2 Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use |
| 08/11/2010 | EP2214652A2 Gastrointestinal delivery systems |
| 08/11/2010 | EP2214646A2 Dendrimers for sustained release of compounds |
| 08/11/2010 | EP2214644A2 Water-immiscible materials as vehicles for drug delivery |
| 08/11/2010 | EP2214643A1 Transdermal delivery system for hormones and steroids |
| 08/11/2010 | EP2214640A1 Intranasal compositions |
| 08/11/2010 | EP2214639A2 Anesthetic composition, formulation and method of use |
| 08/11/2010 | EP2214636A1 Oral dosage forms comprising licarbaz pine acetate |
| 08/11/2010 | EP1827492B1 Antibodies directed to gpnmb and uses thereof |
| 08/11/2010 | EP1796647B1 Stable pegylated interferon formulation |
| 08/11/2010 | EP1633327B1 Method for improving stability and shelf-life of liposome complexes |
| 08/11/2010 | EP1499294B1 Polymerized lipids modified with peptides used as delivery system for micronutrients |
| 08/11/2010 | EP1438073B1 Polyoxyalkylene conjugates as enzyme inhibitors |
| 08/11/2010 | CN1712399B Production and use for taxol and muramic acyl dipeptide conjugate substance of immune reinforcer |
| 08/11/2010 | CN1672745B Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| 08/11/2010 | CN1671357B Short duration depot formulations |
| 08/11/2010 | CN1649551B Drug-delivery endovascular stent and method for treating restenosis |
| 08/11/2010 | CN1429120B Stable polymeric micelle-type drug composition and method for preparation thereof |
| 08/11/2010 | CN101802013A Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
| 08/11/2010 | CN101802012A Anti-CD79b antibodies and immunoconjugates and methods of use |
| 08/11/2010 | CN101801520A Process for producing fine particles and the fine particles |
| 08/11/2010 | CN101801417A Macrophage transfection method |
| 08/11/2010 | CN101801416A Sealmess capsule |
| 08/11/2010 | CN101801415A Sustained delivery formulations of risperidone compounds |
| 08/11/2010 | CN101801414A Oral and skin compositions |
| 08/11/2010 | CN101801404A Protein formulations for use at elevated temperatures |
| 08/11/2010 | CN101801388A Transdermally absorbable preparation |
| 08/11/2010 | CN101801359A Transdermal delivery devices assuring an improved release of an active principle through a biological interface |
| 08/11/2010 | CN101801358A Therapeutic stable nanoparticles |
| 08/11/2010 | CN101801349A Composition and method of stabilized sensitive ingredient |
| 08/11/2010 | CN101801345A lyophilized pharmaceutical compositions |
| 08/11/2010 | CN101801343A antigen-adjuvant compositions and methods |
| 08/11/2010 | CN101801342A methods for producing aripiprazole suspension and freeze-dried formulation |
| 08/11/2010 | CN101801340A Cationic peptide for delivering an agent into a cell |
| 08/11/2010 | CN101801322A Patch material |
| 08/11/2010 | CN101801211A Method for producing stable powder compositions |
| 08/11/2010 | CN101798586A Process for producing aminated complex-type sugar chain derivatives |